Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy and Autoimmune Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for VSIG4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | VSIG4 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View VSIG4 Products |
| Gene Delivery | VSIG4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines, preserving native conformation for cell-based screening. |
View VSIG4 Products |
| Benchmark Ab | Anti-VSIG4 Recombinant Antibody Recombinant positive control derived from clinical benchmark sequences for functional validation. |
View VSIG4 Products |
| Validator | VSIG4 siRNA Set For knockdown verification in primary macrophages or target-expressing cell lines. |
View VSIG4 Products |
| Related Target A | VSIG3 Alternative macrophage-associated immune checkpoint; critical for off-target profiling and synergistic pathway targeting. |
View VSIG3 Products |
| Related Target B | VSIG8 B7-family related checkpoint; essential for subfamily selectivity panels during lead optimization. |
View VSIG8 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus VSIG4 ortholog proteins available with >95% purity verified by SDS-PAGE |
| Subfamily counter screening | Homolog panel proteins (VSIG1, VSIG2, VSIG3, VSIG8) strictly verified by mass spectrometry to ensure assay specificity |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included to validate assay sensitivity and blocking efficiency |
| False Positives in Cell Assays | Validated siRNA included for target-specific knockdown verification in co-culture systems |
Live VSIG4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for VSIG4 therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to bispecific platforms and macrophage-targeted immunotherapies. Originally characterized as a complement receptor (CRIg) critical for clearing opsonized pathogens, VSIG4 has emerged as a potent macrophage-expressed immune checkpoint that strongly suppresses T-cell activation in the tumor microenvironment (TME). As first-generation therapies reach the clinic, the next wave of R&D is targeting bispecific constructs (e.g., VSIG4 x PD-L1) and agonist fusion proteins for autoimmune diseases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Antagonist) | Compugen, Innate Pharma | Solid Tumors, Ovarian Cancer | T-cell suppression reversal assay (Need sequence-verified VSIG4 ECD-Fc) |
| Bispecific Antibody | Preclinical consortia | Cold Tumors, Immune-excluded cancers | Dual-binding kinetics (Need high-purity VSIG4 and co-target proteins) |
| Recombinant Fusion Protein (Agonist) | Academic spin-offs | Rheumatoid Arthritis, Lupus | Complement C3b/iC3b binding inhibition assay (Need endotoxin-controlled proteins) |